Advertisement

An inactivated cell-culture vaccine against yellow fever.

06:25 EDT 22nd May 2013 | BioPortfolio

Summary of "An inactivated cell-culture vaccine against yellow fever."

Yellow fever is a lethal viral hemorrhagic fever occurring in Africa and South America. A highly effective live vaccine (17D) is widely used for travelers to and residents of areas in which yellow fever is endemic, but the vaccine can cause serious adverse events, including viscerotropic disease, which is associated with a high rate of death. A safer, nonreplicating vaccine is needed.

Affiliation

Xcellerex, Marlborough, MA, USA. tmonath@kpcb.com

Journal Details

This article was published in the following journal.

Name: The New England journal of medicine
ISSN: 1533-4406
Pages: 1326-33

Links

Medical and Biotech [MESH] Definitions

Yellow Fever Vaccine

Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.

Poliovirus Vaccine, Inactivated

A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.

Poliovirus Vaccine, Oral

A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)

Rubella Vaccine

A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)

Poliovirus Vaccines

Vaccines used to prevent POLIOMYELITIS. They include inactivated (POLIOVIRUS VACCINE, INACTIVATED) and oral vaccines (POLIOVIRUS VACCINE, ORAL).

PubMed Articles [ 15873 Associated PubMed Articles listed on BioPortfolio]

Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Live, attenuated yellow fever (YF) 17D vaccine is highly efficacious but causes rare, serious adverse events resulting from active replication in the host and direct viral injury to vital organs. We r...

The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.

The changing epidemiology of yellow fever and continued reports of rare but serious adverse events associated with yellow fever vaccine have drawn attention to the need to revisit criteria for the des...

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

Serious, but rare adverse events following immunization (AEFI) have been reported with yellow fever (YF) 17D vaccine, including severe allergic reactions, YF vaccine-associated neurologic disease (YEL...

Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.

There are no data on the use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) as a booster among individuals who previously received inactivated mouse brain-derived...

Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.

A randomized trial was conducted to assess the immunogenicity and reactogenicity of yellow fever vaccines (YFV) given either simultaneously in separate injections, or 30 days or more after a combined...

Clinical Trials [ 5247 Associated Clinical Trials listed on BioPortfolio]

Human Immune Responses to The Yellow Fever Virus Vaccine

The objective of this study is to study immune memory generated against the yellow fever vaccine (YFV) in participants who recently received the YFV vaccine. Volunteers who are planning...

Yellow Fever Virus Vaccine and Immune Globulin Study

The purpose of this study is to determine whether immune globulin can limit the amount of yellow fever vaccine virus present in the blood after vaccination without compromising the immunit...

Trial of Yellow Fever Inactivated Vaccine

The Phase 1 trial is a single-center, randomized, double blind, placebo-controlled, dose-ranging out-patient study designed to provide the first clinical data on the safety, tolerability a...

Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults

The investigators at Rockefeller University are doing this research to study how the immune system responds to viruses and other infectious agents by using the yellow fever 17D vaccine as...

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults

Search BioPortfolio:
Advertisement
Advertisement

Latest Biotech, Pharma and Healthcare News

BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against Yellow Fever in a Preclinical Disease Model

Human medicines European Public Assessment Report (EPAR): Celvapan, influenza vaccine (H1N1)v (whole virion, inactivated, prepared in cell culture), Revision: 7, Authorised

Human medicines European Public Assessment Report (EPAR): Pandemic Influenza Vaccine H5N1 Baxter, pandemic influenza vaccine (whole virion, Vero cell derived, inactivated), Revision: 1, Authorised

Human medicines European Public Assessment Report (EPAR): Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals), pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuva

Human medicines European Public Assessment Report (EPAR): Optaflu, Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Revision: 5, Authorised

Human medicines European Public Assessment Report (EPAR): Vepacel, A/H5N1 pre-pandemic influenza vaccine (whole virion, vero cell derived, inactivated), Revision: 1, Authorised

Human medicines European Public Assessment Report (EPAR): Vepacel, A/H5N1 prepandemic influenza vaccine (whole virion, vero-cell-derived, inactivated), Revision: 1, Authorised


Searches Linking to this Article